Linvoseltamab (LYNOZYFIC ) - a BCMA x CD3 Bispecific Antibody for Multiple Myeloma
Linvoseltamab (Lynozyfic™) is a BCMA-directed bispecific antibody approved for the treatment of relapsed or refractory multiple myeloma. In this video, we explain what linvoseltamab is, how Lynozyfic works, and why this therapy represents an important advance in T-cell–redirecting immunotherapy for myeloma. 👇🔗 Links: • What is CRS lesson on YT: • CRS Explained: Understanding Cytokine Rele... • What is ICANS lesson on YT: • ICANS (Immune Effector Cell-Associated Neu... • Linvoseltamab website: https://www.lynozyfic.com/ 0:00 Introduction 0:11 How does linvoseltamab work? 1:22 How is linvoseltamab administered and dosed 3:25 What is the administration schedule for linvoseltamab? 4:05 Can linvoseltamab be given in a community setting? 4:31 What premedications are given? 5:43 What are the main side effects? 6:21 What are the symptoms of cytokine release syndrome (CRS) 8:08 What other side effects are seen? 8:43. What is ICANS and how common is ICANS? 10:40 Are there any delayed neurotoxicities? 11:35 Should patients be concerned about infections? 13:23 Besides CRS, ICANS and increased infection risks, what other side effects are seen? 15:16 What prophylactic medications are recommended? 17:19 What are recommendations on vaccination? 18:34 What trial confirmed the approval of linvoseltamab? 19:26 What is the linvoseltamab REMS program? 20:16 Can patients respond to linvo if they had previous BCMA-directed therapy? 22:44 What is the role of the caregiver? 23:33 Who is eligible to receive linvoseltamab? 24:52 What is the linvoseltamab wallet card? 25:25 What is the LYNOZYFIC Surround Program? #MultipleMyeloma #Linvoseltamab #Lynozyfic #BCMA #BispecificAntibody #MyelomaTreatment #CancerImmunotherapy #TCellRedirectingTherapy #RelapsedRefractoryMyeloma If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/6286... For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer! Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_so... Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.
Talquetamab (TALVEY) -a GPRC5D x CD3 Bispecific Antibody for Multiple Myeloma
Understanding Your Myeloma Labs: What They Mean, What Matters, and When to Ask Questions
Introduction to Suture
Recent Advances in Multiple Myeloma with Dr. Dan Vogl
Is Multiple Myeloma Fatal? What Experts Say About Living a Normal Life
Ivermectin to Treat Cancer? Get the FACTS
Expanding Myeloma Treatments: Power of Bispecific & Trispecific Antibodies| Dr. Aravind Ramakrishnan
Early Signs of Multiple Myeloma: Symptoms, MGUS, and When to See a Doctor
Your Multiple Myeloma Lab Results, Decoded: What They Mean and What They Don’t
The Complete Cardiology Masterclass: Exam-Ready in One Video
Britain Sold Palestine to Pay Its WWI Debt. The Balfour Declaration Was a Banking Deal!
What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service
This New Histamine Treatment Helped 89% of Patients
Multiple Myeloma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting
Newly Diagnosed Multiple Myeloma | Diagnosis, Initial Treatment | ASCT, Maintenance Therapy, Goals
How to Treat MGUS and Smoldering Myeloma with Dr. S. Vincent Rajkumar
Anktiva's Dirty Secret | Why Many Patients Can't Benefit? #DrPatrickSoon-Shiong #Anktiva
These Two Drugs Eliminated Cancer Metastasis | Here's What You Need to Know
Bi-specific and tri-specific T cell engagers for the treatment of myeloma
